glp 1 receptor agonists beyond their pancreatic effects The Multifaceted Nature of GLP-1: Molecular Mechanisms and Signaling Pathways in Metabolic and Neurodegenerative Diseases GLP-1 actions and target organs.
Description
We adjust the titration schedule rather than push through
doi: 10.1111/dom.13935
Dulaglutide and liraglutide are older GLP-1 agents with less robust weight loss efficacy than newer compounds
Additionally, new non-peptide oral options like Orforglipron are actively in development
Outcome Primary: Cardiovascular outcomes - major adverse cardiovascular events [MACE]
It also slows the emptying of the stomach, enhancing the sensation of fullness after meals
